 |
|
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
Clin Mol Hepatol. 2023;29(3):593-604. Published online 2023 Feb 13 DOI: https://doi.org/10.3350/cmh.2022.0391
|
|
Citations to this article as recorded by
 Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Clinical and Molecular Hepatology.2023; 29(2): 242. CrossRef Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization
Long-Wang Lin, Kun Ke, Le-Ye Yan, Rong Chen, Jing-Yao Huang
Frontiers in Oncology.2023;[Epub] CrossRef Case Report: Clinical application of continuous arterial infusion chemotherapy in neoadjuvant therapy for locally advanced gastric cancer
Wenli Lin, Zhongxian Huang, Zhenhua Du, Yunshan Wang, Taiyang Zuo
Frontiers in Oncology.2023;[Epub] CrossRef
|